Περίληψη:
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments. © 2016 Elsevier Ltd
Συγγραφείς:
Kumar, S.
Paiva, B.
Anderson, K.C.
Durie, B.
Landgren, O.
Moreau, P.
Munshi, N.
Lonial, S.
Bladé, J.
Mateos, M.-V.
Dimopoulos, M.
Kastritis, E.
Boccadoro, M.
Orlowski, R.
Goldschmidt, H.
Spencer, A.
Hou, J.
Chng, W.J.
Usmani, S.Z.
Zamagni, E.
Shimizu, K.
Jagannath, S.
Johnsen, H.E.
Terpos, E.
Reiman, A.
Kyle, R.A.
Sonneveld, P.
Richardson, P.G.
McCarthy, P.
Ludwig, H.
Chen, W.
Cavo, M.
Harousseau, J.-L.
Lentzsch, S.
Hillengass, J.
Palumbo, A.
Orfao, A.
Rajkumar, S.V.
Miguel, J.S.
Avet-Loiseau, H.
Λέξεις-κλειδιά:
bone marrow; computer assisted emission tomography; diagnostic imaging; disease assessment; follow up; human; image analysis; intermethod comparison; long term care; measurement; medical society; minimal residual disease; multiple myeloma; next generation sequencing; nuclear magnetic resonance imaging; organizational downsizing; outcome assessment; polymerase chain reaction; priority journal; quantitative analysis; Review; chemically induced; consensus; multiple myeloma; Neoplasm, Residual; practice guideline; standards, antineoplastic agent, Antineoplastic Combined Chemotherapy Protocols; Consensus; Humans; Multiple Myeloma; Neoplasm, Residual; Practice Guidelines as Topic
